Skip to main navigation Skip to search Skip to main content

A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer

  • Kenneth O’Byrne*
  • , Emilio Esteban
  • , Cheen Leng Lee
  • , Alinta Hegmane
  • , Constantin Volovat
  • , Giuseppe Lo Russo
  • , Dimitrios Ziogas
  • , Akin Atmaca
  • , Martin Sebastian
  • , Margarita Majem
  • *Corresponding author for this work
  • Greenslopes Private Hospital
  • Queensland University of Technology
  • Hospital Universitario Central de Asturias
  • Hospital Pulau Pinang
  • Riga East University Hospital
  • Grigore T. Popa University of Medicine and Pharmacy
  • IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
  • National and Kapodistrian University of Athens
  • Krankenhaus Nordwest, Frankfurt am Main
  • Goethe University Frankfurt
  • Frankfurt Cancer Institute
  • Hospital de La Santa Creu I Sant Pau

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Although immune checkpoint inhibitors (ICIs) form the cornerstone of first-line treatment for non-small cell lung cancer (NSCLC), the challenge remains to improve patients’ long-term outcomes. Eftilagimod alfa (efti) activates antigen-presenting cells, triggering T cell activation and a sustained immune response. Prior studies combining efti with an ICI, pembrolizumab, have shown encouraging efficacy, especially in PD-L1 low (tumor proportion score [TPS] 1–49%) and negative (<1%) tumors. TACTI-004 is a global double-blinded, randomized, placebo-controlled phase III study investigating efti plus standard-of-care (SoC: pembrolizumab plus chemotherapy) in first-line NSCLC, regardless of PD-L1 expression (TPS 0–100%). Patients and methods: About 756 participants with squamous or non-squamous first-line NSCLC, not amenable to EGFR/ROS1/ALK-targeted therapy, will be randomized to receive either efti plus SoC or placebo plus SoC. The dual primary endpoint is progression-free survival and overall survival. Key secondary endpoints include objective response rate, duration of response and safety. Participants will receive 30 mg efti subcutaneously every 2 weeks (q2w) for 24 weeks, then q3w and pembrolizumab 200 mg intravenously q3w, both for up to 2 years. Chemotherapy choice will be histology-dependent. Conclusions: TACTI-004 will evaluate whether efti can mitigate resistance to ICIs when added to SoC in NSCLC, irrespective of PD-L1 tumor status. Clinical Trial Registration: www.clinicaltrials.gov identifier is NCT06726265. Plain Language Summary: Non-small cell lung cancer (NSCLC) is one of the most common cancers in the world. NSCLC is often treated with drugs such as pembrolizumab or chemotherapy; however, new treatment options are needed to improve results for patients. Eftilagimodalfa (efti) is a drug that boosts the immune response to fight tumors. Previous studies have shown that adding efti to pembrolizumab and/or chemotherapy may help immune cells to kill cancer cells. In this study, subjects with NSCLC will receive either: efti + chemotherapy + pembrolizumab or placebo + chemotherapy + pembrolizumab. This study aims to test the effectiveness of these treatments.

Original languageEnglish
Pages (from-to)3885-3890
Number of pages6
JournalFuture Oncology
Volume21
Issue number30
DOIs
Publication statusPublished - 2025
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Clinical trial
  • LAG-3
  • NSCLC
  • PD-1
  • immunotherapy

Fingerprint

Dive into the research topics of 'A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this